Neurix offers a versatile platform to accelerate development of Parkinson’s Disease (PD) drugs, providing in-depth characterisation during the hit-to-lead phase.
Our technology supports drug and compound screening, cell & gene therapy testing and mechanism-of-action studies.
By offering physiologically relevant insights into neurodegenerative processes, Neurix facilitates early-stage discovery and fosters therapeutic innovation.
01.
• Dopaminergic differentiation
• 1 month culture as organoid
02.
Decreased TH, α-synuclein aggregates
Brain organoid growth: viability and proliferation
Representative brightfield or fluorescence pictures of organoid from iPSC control or iPSC with A53T mutation in SNCA gene encoding α-synuclein at 1 month of culture. α-syn. Ab: α-synuclein antibody.
